GlassScriptPhysician profile
Frank Adjei
NPI 1104002765
$3,587.71
in general payments reported to CMS, 2019-2025
30 companies · $734 in 2025
The $734 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,932 · 2020: $261 · 2023: $121 · 2024: $540 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,395.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $461.83 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $303.71 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $299.28 | 2019-2025 | Breztri, Airsupra |
| Lilly USA, LLC | $290.79 | 2019-2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $269.22 | 2019-2024 | |
| Glaxosmithkline, LLC. | $229.36 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.78 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $184.51 | 2019-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $170.33 | 2025 | Auvelity |
| Abbvie INC. | $159.79 | 2019-2025 | |
| Corcept Therapeutics | $121.09 | 2024-2025 | Korlym |
| Allergan, INC. | $119.71 | 2019 | |
| Merck Sharp & Dohme LLC | $108.34 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $90.82 | 2025 | Caplyta |
| Astellas Pharma US INC | $70.83 | 2019-2024 | Veozah |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $69.58 | 2019-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $55.13 | 2025 | |
| Amarin Pharma, INC. | $53.10 | 2019-2020 | |
| Exact Sciences Corporation | $48.92 | 2024-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $45.37 | 2019 | |
| Inspire Medical Systems, INC. | $36.35 | 2025 | Inspire |
| Radius Health, INC. | $31.14 | 2019 | |
| Ironwood Pharmaceuticals, INC | $27.35 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.12 | 2019 | |
| Sumitomo Pharma America, INC. | $23.23 | 2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $22.24 | 2025 | Rexulti |
| Corium, LLC | $16.88 | 2025 | Azstarys |
| Novartis Pharmaceuticals Corporation | $14.13 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.13 | 2019 | |
| Dynavax Technologies Corporation | $11.65 | 2025 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Adjei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.